{
    "clinical_study": {
        "@rank": "40030", 
        "arm_group": [
            {
                "arm_group_label": "Oxcarbazepine first, then Trileptal", 
                "arm_group_type": "Active Comparator", 
                "description": "Single dose of oxcarbazepine suspension, 600 mg, then single dose of trileptal suspension, 600 mg (after washout period)"
            }, 
            {
                "arm_group_label": "Trileptal first, then Oxcarbazepine", 
                "arm_group_type": "Active Comparator", 
                "description": "Single dose of oxcarbazepine suspension, 600 mg, then single dose of trileptal suspension, 600 mg (after washout period"
            }
        ], 
        "brief_summary": {
            "textblock": "The objective of this study was to prove the bioequivalence of  Roxane Laboratories'\n      Oxcarbazepine Suspension 600 mg under fasted conditions."
        }, 
        "brief_title": "Crossover Bioequivalence Study of Oxcarbazepine 600 mg Suspension Under Fasted Conditions", 
        "completion_date": {
            "#text": "September 2009", 
            "@type": "Actual"
        }, 
        "condition": "Seizures", 
        "condition_browse": {
            "mesh_term": "Seizures"
        }, 
        "eligibility": {
            "criteria": {
                "textblock": "Inclusion Criteria:\n\n          -  No clinically significant abnormal findings on the physical examination, medical\n             history, or clinical laboratory results during screening\n\n        Exclusion Criteria:\n\n          -  Positive test for HIV, Hepatitis B, or Hepatitis C.\n\n          -  Treatment with known enzyme altering drugs.\n\n          -  History of allergic or adverse response to oxcarbazepine or any comparable or similar\n             product."
            }, 
            "gender": "Both", 
            "healthy_volunteers": "Accepts Healthy Volunteers", 
            "maximum_age": "45 Years", 
            "minimum_age": "18 Years"
        }, 
        "enrollment": {
            "#text": "64", 
            "@type": "Actual"
        }, 
        "firstreceived_date": "October 4, 2012", 
        "has_expanded_access": "No", 
        "id_info": {
            "nct_id": "NCT01702623", 
            "org_study_id": "OXCA-S600-PVFS-2"
        }, 
        "intervention": {
            "arm_group_label": [
                "Oxcarbazepine first, then Trileptal", 
                "Trileptal first, then Oxcarbazepine"
            ], 
            "intervention_name": "Oxcarbazepine", 
            "intervention_type": "Drug", 
            "other_name": "Trileptal"
        }, 
        "intervention_browse": {
            "mesh_term": [
                "Oxcarbazepine", 
                "Carbamazepine"
            ]
        }, 
        "is_fda_regulated": "No", 
        "lastchanged_date": "January 17, 2014", 
        "location": {
            "facility": {
                "address": {
                    "city": "San Antonio", 
                    "country": "United States", 
                    "state": "Texas", 
                    "zip": "78217"
                }, 
                "name": "Worldwide Clinical Trials Drug Development Solutions (formerly CEDRA Clinical Research)"
            }
        }, 
        "location_countries": {
            "country": "United States"
        }, 
        "number_of_arms": "2", 
        "official_title": "A Single Dose, Two-Period, Two-Treatment, Two-Sequence Crossover Bioequivalence Study of Oxcarbazepine 600 mg Suspension Under Fasted Conditions", 
        "overall_official": {
            "affiliation": "Worldwide Clinical Trials Drug Development Solutions (formerly CEDRA Clinical Research)", 
            "last_name": "Cynthia Zamora, MD", 
            "role": "Principal Investigator"
        }, 
        "overall_status": "Completed", 
        "oversight_info": {
            "authority": "United States: Institutional Review Board", 
            "has_dmc": "No"
        }, 
        "phase": "Phase 1", 
        "primary_completion_date": {
            "#text": "September 2009", 
            "@type": "Actual"
        }, 
        "primary_outcome": {
            "measure": "bioequivalence determined by statistical comparison Cmax", 
            "safety_issue": "No", 
            "time_frame": "10 Days"
        }, 
        "required_header": {
            "download_date": "ClinicalTrials.gov processed this data on June 04, 2014", 
            "link_text": "Link to the current ClinicalTrials.gov record.", 
            "url": "http://clinicaltrials.gov/show/NCT01702623"
        }, 
        "responsible_party": {
            "responsible_party_type": "Sponsor"
        }, 
        "source": "Roxane Laboratories", 
        "sponsors": {
            "lead_sponsor": {
                "agency": "Roxane Laboratories", 
                "agency_class": "Industry"
            }
        }, 
        "start_date": "September 2009", 
        "study_design": "Allocation: Randomized, Endpoint Classification: Bio-equivalence Study, Intervention Model: Crossover Assignment, Masking: Open Label, Primary Purpose: Treatment", 
        "study_type": "Interventional", 
        "verification_date": "January 2014"
    }
}